Brooks Laboratories: Financial Results for the quarter and half year ended September 30, 2026
Brooks Laboratories (BROOKS) filed a disclosure titled "Financial Results for the quarter and half year ended September 30, 2026". The company is valued at about ₹186 crore.
What happened
Brooks Laboratories (BROOKS) filed a disclosure with the exchanges on 7 November 2026 at 05:54 PM titled "Financial Results for the quarter and half year ended September 30, 2026".
From the filing: "The Financial Results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI Listing Regulations in due course."
Company snapshot
Brooks Laboratories is a micro-cap company, with a market value of about ₹186 crore.
The stock last traded at ₹63.25, against a 52-week range of ₹36.3–₹112.4 (43.7% below the high).
Before this filing the shares had moved +7.6% over the month and +5.4% over three months. Average daily turnover over the last 20 sessions was about ₹1.03 crore.
Promoters held 52.62% at the end of Q1 FY27. Foreign institutions owned 0.00% and domestic institutions 10.38%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 26 | 9.6 | 3.25 |
| Q2 FY26 | 23 | 8 | 2.71 |
| Q3 FY26 | 17 | 5.5 | 1.87 |
| Q4 FY26 | 20 | 1.5 | 0.52 |
| Q1 FY27 | 23 | -1.8 | -0.61 |
What history shows
BCEIE's records show 2 previous results filings from the company since May 2026.
Market-wide, 10,949 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 7 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.